NASDAQ:CHMA - Chiasma Stock Price, Forecast & News

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Chiasma Inc (NASDAQ:CHMA) announced its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.01. View Chiasma's Earnings History.

Chiasma is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Chiasma.

6 Wall Street analysts have issued 12-month target prices for Chiasma's shares. Their forecasts range from $11.00 to $18.00. On average, they expect Chiasma's share price to reach $13.80 in the next year. This suggests a possible upside of 189.3% from the stock's current price. View Analyst Price Targets for Chiasma.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chiasma.

Media stories about CHMA stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chiasma earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Chiasma.

Chiasma saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,780,000 shares, an increase of 11.9% from the December 15th total of 1,590,000 shares. Based on an average daily trading volume, of 257,600 shares, the short-interest ratio is presently 6.9 days. Approximately 5.8% of the shares of the company are short sold. View Chiasma's Current Options Chain.

Some companies that are related to Chiasma include Frequency Therapeutics (FREQ), Vanda Pharmaceuticals (VNDA), Eagle Pharmaceuticals (EGRX), CannTrust (CNTTF), Stoke Therapeutics (STOK), TherapeuticsMD (TXMD), ANI Pharmaceuticals (ANIP), Homology Medicines (FIXX), Collegium Pharmaceutical (COLL), Cytokinetics (CYTK), Basilea Pharmaceutica (BPMUF), ImmunoGen (IMGN), Flexion Therapeutics (FLXN), Urogen Pharma (URGN) and DiaMedica Therapeutics (DMCAF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), BioDelivery Sciences International (BDSI), Alnylam Pharmaceuticals (ALNY), Viking Therapeutics (VKTX), Progenics Pharmaceuticals (PGNX), Walgreens Boots Alliance (WBA), Exelixis (EXEL) and Skyworks Solutions (SWKS).

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CHMA stock can currently be purchased for approximately $4.77.

Chiasma has a market capitalization of $200.44 million. The biotechnology company earns $-31,260,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. Chiasma employs 18 workers across the globe.View Additional Information About Chiasma.

The official website for Chiasma is http://www.chiasmapharma.com/.

Chiasma's mailing address is 460 Totten Pond Road Suite 530, Waltham MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]